Phosphodiesterase III inhibitors for heart failure-Reference-Cited by-同舟云学术

Phosphodiesterase III inhibitors for heart failure

Published:2005-01-24 Issue:1 Volume:2013 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Amsallem Emmanuel¹,Kasparian Christelle²,Haddour G³,Boissel Jean-Pierre⁴,Nony Patrice⁵

Affiliation:

1. CETAF; Quality - Evaluation - Etudes; 67-69 Avenue de Rochetaillée - BP 167 Saint-Etienne Cedex 02 France 42012

2. APRET/EZUS; Clinical Pharmacology Unit (EA 3736); Faculte RTH Laennec Rue Guillaume Paradin - BP 8071 Lyon France 69 376

3. Hospices Civils de Lyon; Cardiovscular Hospital Louis Pradel; Lyon France 69 003

4. Hopital Cardio-Vasculaire et Pneumologique Louis Pradel; Centre d'Investigation Clinique - CIC de Lyon; Bron CEDEX France 69677

5. Hopital Neurocardiologique; 28 avenue Doyen Lepine Lyon France 69003

Publisher

Wiley

Subject

Pharmacology (medical)

Reference141 articles.

1. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a muticenter controlled trial;Massie;Circulation,1985

2. Multicenter controlled trial of oral amrinone in congestive heart failure : lack of benefit compared to placebo;Massie;Journal of the American College of Cardiology,1985

3. Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure;Bergler-Klein;Zeitschrift fur Kardiologie,1992

4. Placebo-controlled trial of flosequinan in moderate heart failure. The possible importance of aetiology and method of analysis in the interpretation of the results of heart failure trials;Cowley;International Journal of Cardiology,1993

5. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators;Cowley;British Heart Journal,1994

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of the current use of levosimendan in France: a prospective observational cohort study;Annals of Intensive Care;2023-08-08

2. Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke;European Journal of Clinical Pharmacology;2023-06-13

3. Mutations in Phosphodiesterase 3A ( PDE3A ) Cause Hypertension Without Cardiac Damage;Hypertension;2023-06

4. Phosphodiesterase inhibitors in psychiatric disorders;Psychopharmacology;2023-04-15

5. Integrated Proteomics Unveils Nuclear PDE3A2 as a Regulator of Cardiac Myocyte Hypertrophy;Circulation Research;2023-03-31